The evolution of Taiwan's National Health Insurance drug reimbursement scheme

DARU, Journal of Pharmaceutical Sciences

Volumn 23, Issue 1, 2015, Pages

  Hsu, Jason C ^a   Lu, Christine Y ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Drug policy; Medicines coverage; National Health Insurance; Reimbursement; Taiwan; Universal health coverage

Indexed keywords

ANTACID AGENT; NON PRESCRIPTION DRUG; VITAMIN;

ARTICLE; DRUG COST; DRUG INDUSTRY; DRUG REIMBURSEMENT; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HUMAN; NATIONAL HEALTH INSURANCE; PHARMACIST; PHYSICIAN; PRIMARY MEDICAL CARE; REIMBURSEMENT; SMOKING CESSATION; TAIWAN; COST CONTROL; ECONOMICS; HEALTH CARE COST; LEGISLATION AND JURISPRUDENCE; PHARMACOECONOMICS; PUBLIC HEALTH; TRENDS;

COST CONTROL; ECONOMICS, PHARMACEUTICAL; HEALTH EXPENDITURES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; NATIONAL HEALTH PROGRAMS; TAIWAN;

EID: 84924228358     PISSN: 15608115     EISSN: 20082231     Source Type: Journal    
DOI: 10.1186/s40199-014-0080-7     Document Type: Article

References (35)

1. Hogerzeil H: Access to essential medicines as a human right. World Health Organisation: Essential Drugs Monitor 2003, (33):25-26. http://apps.who.int/medicinedocs/en/d/Js4941e/5.html.
2. Gil-Gonzalez D, Carrasco-Portino M, Vives-Cases C, Agudelo-Suarez AA, Castejon Bolea R, Ronda-Perez E: Is health a right for all? An umbrella review of the barriers to health care access faced by migrants. Ethn Health 2014, 13:1-19.
3. National Health Insurance Administration. Website. http://www.nhi.gov.tw/english/index.aspx.
4. Mullins CD, Wang J, Palumbo FB, Stuart B: The impact of pipeline drugs on drug spending growth. Health Aff (Millwood) 2001, 20(5):210-215.
5. Berndt ER: Pharmaceuticals in U.S. health care: determinants of quantity and price. J Econ Perspect 2002, 16(4):45-66.
6. Levit K, Smith C, Cowan C, Sensenig A, Catlin A: Health spending rebound continues in 2002. Health Aff (Millwood) 2004, 23(1):147-159.
7. Hsieh CR, Sloan FA: Adoption of pharmaceutical innovation and the growth of drug expenditure in Taiwan: is it cost effective? Value Health 2008, 11(2):334-344.
8. Yang CL, Chao HL, Huang WY, Lin WD, Huang KH, Lai MS: National Health Insurance. Taiwan: Wagner Co Ltd; 2012.
9. Huang SK, Tsai SL, Hsu MT: Ensuring the sustainability of the Taiwan National Health Insurance. J Formos Med Assoc 2014, 113(1):1-2.
10. National Health Insurance Act. Website http://mohwlaw.mohw.gov.tw/Chi/EngContent.asp?msgid=279&KeyWord=%A5%FE%A5%C1%B0%B7%B1d%ABO% C0I%AAk.
11. National Health Insurance Administration: The National Health Insurance Pharmaceutical Benefits and Reimbursement Schedule. Taiwan: National Health Insurance Administration; 2014. http://law.moj.gov.tw/Eng/LawClass/LawContent.aspx?PCODE=L0060035.
12. Huang CM: The Reform Strategy of NHI drug Expenditure Rationalization. Taiwan: The Bureau of National Health Insurance; 1998.
13. Cheng C, Hsieh CR: Economic analysis of NHI pharmaceutical policies and drug expenditures. Socioecon Law Inst Rev 2005, 35:1-42.
14. Cheng C: An Analysisi of NHI Drug Policies and Pharmaceutical Expenditures. Taiwan: Chang Gung University; 2003.
15. Huang HH, Shen MC, Liu HS: National Health Insurance. Taiwan: Wu-nan Book Inc; 2012.
16. Yang BM: The future of health technology assessment in healthcare decision making in Asia. Pharmacoeconomics 2009, 27(11):891-901.
17. Chen CL, Chen L, Yang WC: The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs. BMC Public Health 2008, 8:118.
18. Hsu JC, Lu CY, Wagner AK, Chan KA, Lai MS, Ross-Degnan D: Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study. Health Policy 2014, 116(2-3):196-205.
19. Lee YC, Yang MC, Huang YT, Liu CH, Chen SB: Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003. Pharmacoeconomics 2006, 24(9):891-902.
20. Chu HL, Liu SZ, Romeis JC: Changes in prescribing behaviors after implementing drug reimbursement rate reduction policy in Taiwan: implications for the medicare system. J Health Care Finance 2008, 34(3):45-54.
21. Hsiao FY, Tsai YW, Huang WF: Price regulation, new entry, and information shock on pharmaceutical market in Taiwan: a nationwide data-based study from 2001 to 2004. BMC Health Serv Res 2010, 10:218.
22. Chu HL, Liu SZ, Romeis JC: Assessing the effects of drug price reduction policies on older people in Taiwan. Health Serv Manage Res 2011, 24(1):1-7.
23. Weekes LM, Mackson JM, Fitzgerald M, Phillips SR: National Prescribing Service: creating an implementation arm for national medicines policy. Br J Clin Pharmacol 2005, 59(1):112-116.
24. Lu CY, Ross-Degnan D, Stephens P, Liu BAW: Changes in use of antidiabetic medications following price regulations in China. J Pharm Health Serv Res 2013, 4:3-11.
25. Jirawattanapisal T, Kingkaew P, Lee TJ, Yang MC: Evidence-based decisionmaking in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan. Value Health 2009, 12(Suppl 3):S4-S11.
26. Yan YH, Chen Y, Kung CM, Peng LJ: Continuous quality improvement of nursing care: case study of a clinical pathway revision for cardiac catheterization. J Nurs Res 2011, 19(3):181-189.
27. Schmid A, Cacace M, Gotze R, Rothgang H: Explaining health care system change: problem pressure and the emergence of hybrid health care systems. J Health Polit Policy Law 2010, 35(4):455-486.
28. Busato A, von Below G: The implementation of DRG-based hospital reimbursement in Switzerland: A population-based perspective. Health Res Policy Syst 2010, 8:31.
29. Chen PC, Lee YC, Kuo RN: Differences in patient reports on the quality of care in a diabetes pay-for-performance program between 1 year enrolled and newly enrolled patients. Int J Qual Health Care 2012, 24(2):189-196.
30. Cheng SH, Lee TT, Chen CC: A longitudinal examination of a pay-forperformance program for diabetes care: evidence from a natural experiment. Med Care 2012, 50(2):109-116.
31. Sivalal S: Health technology assessment in the Asia Pacific region. Int J Technol Assess Health Care 2009, 25(Suppl 1):196-201.
32. Kamae I: Value-based approaches to healthcare systems and pharmacoeconomics requirements in Asia: South Korea, Taiwan, Thailand and Japan. Pharmacoeconomics 2010, 28(10):831-838.
33. Lu C, Lupton C, Rakowsky S, Ross-Degnan D, Wagner A: Patient access schemes in asia-pacific markets: current experience and future potential. J Pharm Policy Pract 2014. in press.
34. Lu CY, Williams K, Day R, March L, Sansom L, Bertouch J: Access to high cost drugs in Australia. BMJ 2004, 329(7463):415-416.
35. Hall WD, Ward R, Liauw WS, Lu CY, Brien JA: Tailoring access to high cost, genetically targeted drugs. Med J Aust 2005, 182(12):607-608.